NeOnc Secures $16M PIPE, Advances NEO212 to 610 mg Phase 2 Dose
NeOnc Technologies completed Phase 1 dose escalation for oral NEO212, establishing a 610 mg Phase 2 dose with early signs of disease control in recurrent glioblastoma. Intranasal NEO100 Phase 2 data showed improved progression-free survival versus historical benchmarks, and a recent $16 million PIPE bolstered its balance sheet despite a 0.1% share decline on light volume.
1. Oral NEO212 Phase 1 Advancement
NeOnc completed Phase 1 dose escalation of its oral NEO212 chemotherapy in recurrent glioblastoma, establishing 610 mg as the recommended Phase 2 dose and reporting early signs of disease control in patients who had progressed on standard temozolomide.
2. Intranasal NEO100 Phase 2 Data
The company’s intranasal NEO100 program reported Phase 2 radiographic responses and improved progression-free survival compared with historical salvage benchmarks, validating its non-invasive CNS delivery platform.
3. $16 Million PIPE Offering
NeOnc raised $16.0 million through a private investment in public equity, significantly boosting its cash position to support ongoing development of NEO212, NEO100 and additional CNS oncology programs.
4. Recent Trading Activity
Shares of NeOnc slipped 0.1% to $9.41 on light trading volume of 13,768 shares, down 76% from its 56,570-share average daily volume, reflecting investor caution despite positive clinical updates.